Shopping Cart 0
Cart Subtotal
AED 0

Oragenics Inc (OGEN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753

Details

Summary

Oragenics Inc (Oragenics) focuses on the development and commercialization of novel antibiotics against infectious disease that includes treatments for oral mucositis, healthcare associated infections, obesity and dental disorders. The company develops its product candidates based on various technologies such as Lantibiotics which is a class of antibiotics with a novel mechanism of action active against several multi-drug resistant organisms; live biotherapeutics, which utilizes genetically modified bacteria to treat oral indications and SMaRT Replacement Therapy which is based on the creation of genetically modified strain of bacteria colonizing in the oral cavity and replaces native bacteria that cause tooth decay. Oragenics is headquartered in Tampa, Florida, the US.

Oragenics Inc (OGEN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Oragenics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Oragenics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Oragenics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Oragenics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Oragenics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Oragenics Inc, Pharmaceuticals & Healthcare, Deal Details 10

Partnerships 10

Intrexon Enters into Co-Development Agreement with Oragenics 10

Licensing Agreements 11

Oragenics Enters Into Licensing Agreement With Intrexon For Lantibiotics 11

Equity Offering 13

Oragenics Raises USD13.8 Million Public Offering of Shares and Warrants 13

Oragenics Prices Private Placement of Shares for USD1.8 Million 15

Oragenics Raises USD3.3 Million in Rights Offering of Preferred Shares 16

Oragenics Raises USD6.7 Million in Private Placement of Shares 17

Oragenics Raises USD1.7 Million in Second Tranche of Private Placement of Series A Preferred Stock 18

Oragenics Raises USD1.3 Million in First Tranche of Private Placement of Series A Preferred Stock 19

Oragenics Raises USD4.7 Million in Private Placement of Shares 20

Oragenics Completes Public Offering Of Shares For USD 11 Million 22

Oragenics Completes Private Placement Of Shares For USD 4 Million 23

Oragenics Completes Private Placement Of Common Stock For USD 13 Million 24

Asset Transactions 25

Oragenics Sells Certain Probiotic Business Assets to ProBiora Health 25

Oragenics Inc-Key Competitors 26

Oragenics Inc-Key Employees 27

Oragenics Inc-Locations And Subsidiaries 28

Head Office 28

Other Locations & Subsidiaries 28

Recent Developments 29

Financial Announcements 29

Apr 18, 2017: Oragenics Provides First Quarter 2017 Update 29

Product News 30

06/06/2017: Oragenics Presents Development of Novel Lantibiotic Against Clostridium difficile at the ICAAC Conference 30

03/19/2018: Oragenics Announces Peer Reviewed Publication Examining Efficacy of Mutacin 1140 Lantibiotic Variants against Clostridium difficile 31

Clinical Trials 32

Mar 23, 2018: Oragenics Completes Enrollment for the Interim Analysis Cohort in Its Phase 2 Clinical Trial of AG013 for Oral Mucositis 32

Aug 31, 2017: Oragenics Doses First Patient in Phase 2 Clinical Trial of AG013 for Oral Mucositis 33

Appendix 34

Methodology 34

About GlobalData 34

Contact Us 34

Disclaimer 34


List Of Figure

List of Figures

Oragenics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Oragenics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Oragenics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Oragenics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Oragenics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Oragenics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Oragenics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Oragenics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Oragenics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Oragenics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Oragenics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Oragenics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Oragenics Inc, Deals By Therapy Area, 2012 to YTD 2018 8

Oragenics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Intrexon Enters into Co-Development Agreement with Oragenics 10

Oragenics Enters Into Licensing Agreement With Intrexon For Lantibiotics 11

Oragenics Raises USD13.8 Million Public Offering of Shares and Warrants 13

Oragenics Prices Private Placement of Shares for USD1.8 Million 15

Oragenics Raises USD3.3 Million in Rights Offering of Preferred Shares 16

Oragenics Raises USD6.7 Million in Private Placement of Shares 17

Oragenics Raises USD1.7 Million in Second Tranche of Private Placement of Series A Preferred Stock 18

Oragenics Raises USD1.3 Million in First Tranche of Private Placement of Series A Preferred Stock 19

Oragenics Raises USD4.7 Million in Private Placement of Shares 20

Oragenics Completes Public Offering Of Shares For USD 11 Million 22

Oragenics Completes Private Placement Of Shares For USD 4 Million 23

Oragenics Completes Private Placement Of Common Stock For USD 13 Million 24

Oragenics Sells Certain Probiotic Business Assets to ProBiora Health 25

Oragenics Inc, Key Competitors 26

Oragenics Inc, Key Employees 27

Oragenics Inc, Other Locations 28

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Oragenics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Oragenics Inc (Oragenics) focuses on the development and commercialization of novel antibiotics against infectious disease that includes treatments for oral mucositis, healthcare associated infections, obesity and dental disorders. The company develops its product candidates based on various technologies such as Lantibiotics which is a class of antibiotics with a novel mechanism of action active against several multi-drug resistant organisms; live biotherapeutics, which utilizes genetically modified bacteria to treat oral indications and SMaRT Replacement Therapy which is based on the creation of genetically modified strain of bacteria colonizing in the oral cavity and replaces native bacteria that cause tooth decay. Oragenics is headquartered in Tampa, Florida, the US.

Oragenics Inc (OGEN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Oragenics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Oragenics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Oragenics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Oragenics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Oragenics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Oragenics Inc, Pharmaceuticals & Healthcare, Deal Details 10

Partnerships 10

Intrexon Enters into Co-Development Agreement with Oragenics 10

Licensing Agreements 11

Oragenics Enters Into Licensing Agreement With Intrexon For Lantibiotics 11

Equity Offering 13

Oragenics Raises USD13.8 Million Public Offering of Shares and Warrants 13

Oragenics Prices Private Placement of Shares for USD1.8 Million 15

Oragenics Raises USD3.3 Million in Rights Offering of Preferred Shares 16

Oragenics Raises USD6.7 Million in Private Placement of Shares 17

Oragenics Raises USD1.7 Million in Second Tranche of Private Placement of Series A Preferred Stock 18

Oragenics Raises USD1.3 Million in First Tranche of Private Placement of Series A Preferred Stock 19

Oragenics Raises USD4.7 Million in Private Placement of Shares 20

Oragenics Completes Public Offering Of Shares For USD 11 Million 22

Oragenics Completes Private Placement Of Shares For USD 4 Million 23

Oragenics Completes Private Placement Of Common Stock For USD 13 Million 24

Asset Transactions 25

Oragenics Sells Certain Probiotic Business Assets to ProBiora Health 25

Oragenics Inc-Key Competitors 26

Oragenics Inc-Key Employees 27

Oragenics Inc-Locations And Subsidiaries 28

Head Office 28

Other Locations & Subsidiaries 28

Recent Developments 29

Financial Announcements 29

Apr 18, 2017: Oragenics Provides First Quarter 2017 Update 29

Product News 30

06/06/2017: Oragenics Presents Development of Novel Lantibiotic Against Clostridium difficile at the ICAAC Conference 30

03/19/2018: Oragenics Announces Peer Reviewed Publication Examining Efficacy of Mutacin 1140 Lantibiotic Variants against Clostridium difficile 31

Clinical Trials 32

Mar 23, 2018: Oragenics Completes Enrollment for the Interim Analysis Cohort in Its Phase 2 Clinical Trial of AG013 for Oral Mucositis 32

Aug 31, 2017: Oragenics Doses First Patient in Phase 2 Clinical Trial of AG013 for Oral Mucositis 33

Appendix 34

Methodology 34

About GlobalData 34

Contact Us 34

Disclaimer 34


List Of Figure

List of Figures

Oragenics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Oragenics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Oragenics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Oragenics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Oragenics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Oragenics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Oragenics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Oragenics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Oragenics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Oragenics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Oragenics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Oragenics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Oragenics Inc, Deals By Therapy Area, 2012 to YTD 2018 8

Oragenics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Intrexon Enters into Co-Development Agreement with Oragenics 10

Oragenics Enters Into Licensing Agreement With Intrexon For Lantibiotics 11

Oragenics Raises USD13.8 Million Public Offering of Shares and Warrants 13

Oragenics Prices Private Placement of Shares for USD1.8 Million 15

Oragenics Raises USD3.3 Million in Rights Offering of Preferred Shares 16

Oragenics Raises USD6.7 Million in Private Placement of Shares 17

Oragenics Raises USD1.7 Million in Second Tranche of Private Placement of Series A Preferred Stock 18

Oragenics Raises USD1.3 Million in First Tranche of Private Placement of Series A Preferred Stock 19

Oragenics Raises USD4.7 Million in Private Placement of Shares 20

Oragenics Completes Public Offering Of Shares For USD 11 Million 22

Oragenics Completes Private Placement Of Shares For USD 4 Million 23

Oragenics Completes Private Placement Of Common Stock For USD 13 Million 24

Oragenics Sells Certain Probiotic Business Assets to ProBiora Health 25

Oragenics Inc, Key Competitors 26

Oragenics Inc, Key Employees 27

Oragenics Inc, Other Locations 28

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Oragenics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.